0001104659-23-106379.txt : 20231003
0001104659-23-106379.hdr.sgml : 20231003
20231003160134
ACCESSION NUMBER: 0001104659-23-106379
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brenner Martin
CENTRAL INDEX KEY: 0001770235
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35023
FILM NUMBER: 231303386
MAIL ADDRESS:
STREET 1: C/O PFENEX INC.
STREET 2: 10790 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iBio, Inc.
CENTRAL INDEX KEY: 0001420720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262797813
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
BUSINESS PHONE: 302 355-0650
MAIL ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
FORMER COMPANY:
FORMER CONFORMED NAME: iBioPharma, Inc.
DATE OF NAME CHANGE: 20080806
FORMER COMPANY:
FORMER CONFORMED NAME: InB:Biotechnologies, Inc.
DATE OF NAME CHANGE: 20071210
4
1
tm2327541-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-10-02
0
0001420720
iBio, Inc.
IBIO
0001770235
Brenner Martin
C/O IBIO, INC.
8800 HSC PARKWAY
BRYAN
TX
77807
0
1
0
0
See Remarks
0
Common Stock
2023-10-02
4
S
0
4215
0.3110
D
192650
D
The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. (the "Issuer").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3100 to $0.3129 inclusive. The Reporting Person undertakes to provide to the Issuer, any securities holder of the Issuer, or the staff of the Securities and Exchange Commission, upon report, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Chief Executive Officer and Chief Scientific Officer
/s/ Martin Brenner
2023-10-03